Abstract Library

#4398 The role of chromogranin A as a biomarker in neuroendocrine tumours: Diagnostic and prognostic implications

Introduction: Chromogranin A (CgA) is a widely used serum biomarker for neuroendocrine tumours (NETs), reflecting tumour burden and secretory activity. Despite its clinical utility, the diagnostic sensitivity and prognostic value of CgA remain a subject of debate, especially given its potential for false positives and its variation across different NET subtypes.

Conference:

Presenting Author:

Authors: Xu L, Ye M, Zeng X, Chen S, Ding Y,

Keywords: Chromogranin A, neuroendocrine tumour, diagnosis, prognosis, biomarker, Ki-67, metastatic disease,

#4396 Hypoxic microenvironment in neuroendocrine tumours

Introduction: The hypoxic microenvironment is a hallmark of many solid tumours, including neuroendocrine tumours (NETs). Hypoxia plays a crucial role in tumour progression, metastasis, and therapy resistance. However, the specific mechanisms by which hypoxia influences NET behaviour remain poorly understood.

Conference:

Presenting Author:

Authors: Xu L, Yu P, Ye M, Chen J, Tang Q,

Keywords: Neuroendocrine tumour, hypoxia, HIF-1α, VEGF, mTOR, PI3K/AKT, drug resistance, EMT,

#4395 Mechanisms of drug resistance in neuroendocrine tumours: A basic research study

Introduction: Neuroendocrine tumours (NETs) often show resistance to chemotherapy and targeted therapies, leading to treatment failure. However, the molecular mechanisms underlying this resistance remain poorly understood.

Conference:

Presenting Author:

Authors: Xu L, Yu P, Chen J, Ye M, Xue B,

Keywords: Neuroendocrine tumour, drug resistance, mTOR, PI3K/AKT, tumour microenvironment, chemotherapy,

#4382 Sensitivity of endoscopic ultrasound in detecting small gastrointestinal neuroendocrine tumours

Introduction: Small gastrointestinal neuroendocrine tumours (GI-NETs) are often difficult to detect using conventional imaging modalities, leading to delayed diagnosis and suboptimal treatment outcomes. Endoscopic ultrasound (EUS) has emerged as a promising tool for the early detection and precise localisation of these tumours. However, its sensitivity in identifying small lesions remains to be thoroughly evaluated.

Conference:

Presenting Author:

Authors: Xu L, Ye M, Xue B, Tang Q,

Keywords: Endoscopic ultrasound, small gastrointestinal neuroendocrine tumour, early detection, imaging modalities,

#4319 Everolimus combined with orlistat inhibits the development of neuroendocrine tumours by inhibiting the mTOR-PI3K-Akt signalling pathway

Introduction: Everolimus, an mTOR inhibitor, has demonstrated efficacy in NET treatment. Orlistat, used primarily for obesity management, inhibits fat absorption. This study investigates the potential synergistic effects of Everolimus combined with Orlistat on the development of NETs.

Conference:

Presenting Author:

Authors: Xu L, Tang Q, Ye M,

Keywords: Everolimus, orlistat, mTOR, PI3K/Akt, signalling pathway,